Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker (ADIRAS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by Slovak Academy of Sciences.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Stefan Zorad, Slovak Academy of Sciences
ClinicalTrials.gov Identifier:
NCT01444833
First received: September 19, 2011
Last updated: September 29, 2011
Last verified: September 2011
  Purpose

It is supposed that the significant metabolic effects (improvement of insulin sensitivity) of hypertension therapy with renin-angiotensin system (RAS) blockers in humans are mediated mainly via changes in abdominal adipose tissue. This project is aimed to confirm the hypothesis that increased concentrations of circulatory angiotensin II after angiotensin II receptor type I (AT1) blockade leads, via stimulation of angiotensin II receptor type II (AT2), to activation of adipogenesis and improvement of insulin sensitivity. Therefore, in hypertensive patients, the components of RAS and the parameters of insulin sensitivity on systemic (in plasma) and local (in adipose tissue and in its interstitial fluid) level will be studied. The main aim of the study is to identify the changes occurring in patient before and 6 months after the conversion of therapy from angiotensin converting enzyme (ACE) inhibitors to AT1 receptor blockers. Observed parameters will include gene expression of RAS components, parameters of insulin sensitivity, amount, and cellularity of adipose tissue obtained by biopsy, evaluation of direct production of cytokines and angiotensins into the interstitial fluid of fat tissue obtained by microdialysis and evaluation of the selected parameters in plasma.


Condition Intervention
Hypertension
Drug: Candesartan

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension

Resource links provided by NLM:


Further study details as provided by Slovak Academy of Sciences:

Primary Outcome Measures:
  • Systemic Insulin Sensitivity after Replacement of ACE Inhibitor by AT1 Blocker [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Oral glucose tolerance test (OGTT) will be used to determine systemic insulin sensitivity.


Secondary Outcome Measures:
  • Adipocyte Diameter from Subcutaneous Adipose Tissue after Replacement ACE Inhibitor by AT1 Blocker [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The tissue obtai ned by biopsy will be digested by collagenase and the diameter of isolated adipocytes will be evaulated by light microscopy.


Estimated Enrollment: 35
Study Start Date: October 2008
Estimated Study Completion Date: December 2012
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Candesartan
    32 mg per day duration 6 months
    Other Name: Atacand
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   25 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • essential hypertension
  • ACE inhibitors

Exclusion Criteria:

  • diabetes mellitus
  • endocrinopathies
  • no smokers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01444833

Contacts
Contact: Stefan Zorad, Dr. 00421 2 54772800 ext 250 stefan.zorad@savba.sk
Contact: Adrian Oksa, MD. 00421 2 59370 ext 628 adrian.oksa@szu.sk

Locations
Slovakia
Institute of Experimental Endocrinology, SAS Recruiting
Bratislava, Slovakia, 833 06
Contact: Stefan Zorad, Dr.    00421 2 54772800 ext 250    stefan.zorad@savba.sk   
Contact: Adela Penesova, MD.    00421 2 54772800 ext 260    adela.penesova@savba.sk   
Principal Investigator: Richard Imrich, MD.         
Principal Investigator: Katarina Krskova, Dr.         
Principal Investigator: Miroslav Vlcek, MD.         
Sub-Investigator: Adrian Oksa, MD.         
Sponsors and Collaborators
Slovak Academy of Sciences
Investigators
Principal Investigator: Stefan Zorad, Dr. Institute of Experimental Endocrinology SAS
  More Information

Publications:

Responsible Party: Stefan Zorad, Head of Laboratory, Slovak Academy of Sciences
ClinicalTrials.gov Identifier: NCT01444833     History of Changes
Other Study ID Numbers: MinHealth, 2007/27-SAV-02
Study First Received: September 19, 2011
Last Updated: September 29, 2011
Health Authority: Slovak Republic: Ethics Committee

Keywords provided by Slovak Academy of Sciences:
hypertension
obesity
metabolism
angiotensin

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 29, 2014